GlassScriptPhysician profile
Patrick G Meade
NPI 1710983572
$8,161.25
in general payments reported to CMS, 2019-2025
43 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $570 · 2021: $1,099 · 2022: $1,372 · 2023: $1,478 · 2024: $1,760 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,487.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.14 | 2019-2025 | |
| Lilly USA, LLC | $920.61 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $830.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $566.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $553.41 | 2019-2025 | |
| Amgen INC. | $393.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $287.92 | 2019-2025 | Breztri |
| Astellas Pharma US INC | $267.88 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.61 | 2020-2024 | Jardiance |
| Axsome Therapeutics, INC. | $211.65 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.14 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $183.19 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $153.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $148.25 | 2019-2024 | Vaxelis, Capvaxive, Gardasil |
| Allergan, INC. | $141.73 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.